Amgen's Leerink Conference Reiteration Underscores Obesity Dependence and Valuation Risks

What happened

Amgen's management presented at the Leerink Global Healthcare Conference, likely emphasizing the MariTide obesity franchise's Phase 3 progress and Horizon asset integration to drive growth. They probably reiterated 2026 guidance, aiming to offset known declines in legacy products like ENBREL and Otezla from IRA price cuts. However, the presentation glosses over immediate headwinds, including a 38% net price drop for ENBREL in Q3 2025 and biosimilar erosion for Prolia and XGEVA starting in 2026. Management's optimism on obesity faces a crowded GLP-1 market with entrenched competitors, and Phase 3 data remains years away, leaving execution risks high. Investors must weigh these updates against a stock trading at ~23.7x P/E, which already discounts significant success while leverage and tax disputes linger.

Implication

The presentation highlights Amgen's heavy reliance on MariTide for long-term growth, but Phase 3 outcomes are distant, exposing the near term to certain legacy erosion and pricing pressure. Horizon assets must consistently outperform to offset declines, yet any hiccups could strain margins and delay deleveraging. Policy-driven headwinds from IRA and biosimilars are immediate, compressing cash flows and limiting valuation support. With the stock priced for perfection, downside risks outweigh upside potential unless MariTide delivers beyond expectations. Therefore, awaiting a pullback below $295, as per the DeepValue report, remains prudent to mitigate asymmetric risks.

Thesis delta

The conference presentation does not shift the investment thesis; it confirms that Amgen's narrative remains centered on obesity and Horizon, with no new data to alter the risk-reward skew. Structural headwinds and high valuation persist, reinforcing the 'POTENTIAL SELL' rating and the need for a better entry point around $295 to account for execution uncertainties.